{"id":"individualized-pharmacokinetically-driven-paclitaxel-dosing","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Myalgia/arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach uses therapeutic drug monitoring and pharmacokinetic modeling to personalize paclitaxel dosing, aiming to achieve target drug exposure while minimizing toxicity. Rather than using fixed body surface area-based dosing, this strategy calculates individual clearance rates and adjusts subsequent doses to maintain optimal plasma concentrations, potentially improving efficacy and tolerability.","oneSentence":"Individualized pharmacokinetically driven paclitaxel dosing optimizes chemotherapy exposure by adjusting paclitaxel doses based on each patient's real-time drug clearance and pharmacokinetic parameters.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:57.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors (paclitaxel-responsive cancers including ovarian, breast, and lung cancers)"}]},"trialDetails":[{"nctId":"NCT01326767","phase":"PHASE3","title":"Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring","status":"COMPLETED","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2011-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":366}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Individualized pharmacokinetically driven paclitaxel dosing","genericName":"Individualized pharmacokinetically driven paclitaxel dosing","companyName":"Central European Society for Anticancer Drug Research","companyId":"central-european-society-for-anticancer-drug-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Individualized pharmacokinetically driven paclitaxel dosing optimizes chemotherapy exposure by adjusting paclitaxel doses based on each patient's real-time drug clearance and pharmacokinetic parameters. Used for Various solid tumors (paclitaxel-responsive cancers including ovarian, breast, and lung cancers).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}